Belpointe Asset Management’s Heron Therapeutics HRTX Stock Holding History

Belpointe Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-104	Closed	-$260	–	3781
2022 Q4	$260	Buy	+104	New	+$335	﹤0.01%	3612
2021 Q1	–	Sell	-7,871	Closed	-$166K	–	1032
2020 Q4	$166K	Sell	7,871 -6,429	-45%	-$112K	0.01%	765
2020 Q3	$212K	Hold	14,300	–	–	0.02%	527
2020 Q2	$210K	Buy	14,300 +1,100	+8%	+$18.1K	0.03%	514
2020 Q1	$155K	Sell	13,200 -2,600	-16%	-$48.9K	0.03%	488
2019 Q4	$371K	Hold	15,800	–	–	0.05%	391
2019 Q3	$292K	Buy	15,800 +2,407	+18%	+$44.3K	0.05%	396
2019 Q2	$249K	Buy	13,393 +193	+1%	+$3.85K	0.05%	364
2019 Q1	$323K	Buy	+13,200	New	+$346K	0.06%	233

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Belpointe Asset Management's HRTX Position: Q1 2023 in Review

Belpointe Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 104 shares — an estimated $260 sold.

Belpointe Asset Management first reported a position in HRTX in Q1 2019 and held it in 9 quarters. The position peaked at $371K in Q4 2019. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

Belpointe Asset Management reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
Belpointe Asset Management sold 104 Heron Therapeutics shares in Q1 2023, an estimated $260.
Belpointe Asset Management first reported a position in Heron Therapeutics in Q1 2019 and held it in 9 quarters.
Belpointe Asset Management's Heron Therapeutics position peaked at $371K in Q4 2019.
162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.